Direct comparison of transvenous and leadless Bachmann bundle area pacing in the same patient Authors: Zachary T. Hollis, Eunice Yang, Brett D. Atwater Published: 2026 Key Teaching Points •Conduction system pacing at Bachmann bundle area can overcome intra-atrial conduction delay.•Correcting intra atrial conduction delay can decrease left atrium pressure, atrial fibrillation incidence, and heart failure incidence.•Successful leadless pacing at the Bachmann bundle area is as effective as transvenous Bachmann bundle area pacing.•Intracardiac echocardiography and left lateral atrial activation time are useful in confirming Bachmann bundle area pacing. Key Teaching Points •Conduction system pacing at Bachmann bundle area can overcome intra-atrial conduction delay.•Correcting intra atrial conduction delay can decrease left atrium pressure, atrial fibrillation incidence, and heart failure incidence.•Successful leadless pacing at the Bachmann bundle area is as effective as transvenous Bachmann bundle area pacing.•Intracardiac echocardiography and left lateral atrial activation time are useful in confirming Bachmann bundle area pacing. •Conduction system pacing at Bachmann bundle area can overcome intra-atrial conduction delay. Conduction system pacing at Bachmann bundle area can overcome intra-atrial conduction delay. •Correcting intra atrial conduction delay can decrease left atrium pressure, atrial fibrillation incidence, and heart failure incidence. Correcting intra atrial conduction delay can decrease left atrium pressure, atrial fibrillation incidence, and heart failure incidence. •Successful leadless pacing at the Bachmann bundle area is as effective as transvenous Bachmann bundle area pacing. Successful leadless pacing at the Bachmann bundle area is as effective as transvenous Bachmann bundle area pacing. •Intracardiac echocardiography and left lateral atrial activation time are useful in confirming Bachmann bundle area pacing. Intracardiac echocardiography and left lateral atrial activation time are useful in confirming Bachmann bundle area pacing. Introduction Conduction system pacing (CSP) may prevent pacing-induced ventricular dyssynchrony and cardiomyopathy and is an alternative to biventricular pacing for cardiac resynchronization therapy in patients with dyssynchronous cardiomyopathy from conduction block. Similarly, atrial CSP through Bachmann bundle (BB) area (BBA) pacing (BBAP) has been proposed as a means to restore physiologic atrial activation, reduce interatrial conduction delay (IACD), and reduce risk of subsequent atrial fibrillation (AF).1, 2, 3, 4, 5, 6 BBAP restores intra-atrial synchrony in patients with underlying IACD, compared with right atrial appendage pacing, and optimizes electrocardiography (ECG) characteristics predictive of AF.7 Leadless atrial pacing targeting the BBA may be a suitable alternative to transvenous pacing and has previously been shown to provide atrial resynchronization.8 We report what we believe is the first direct comparison of BBAP using transvenous and leadless approaches. Case report A 74 year-old man with a history of sinus node dysfunction (SND) and right bundle branch block (RBBB) presented for transvenous dual chamber pacemaker implantation owing to presyncope and marked bradycardia. His medical history was notable for hypertension, polycystic kidney disease, and sinus node dysfunction. The ejection fraction was 69%. The patient’s baseline sinus rhythm 12-lead ECG revealed low-amplitude bimodal P waves with a duration of 120 ms and an inferiorly directed axis. Owing to sinus node dysfunction, prolonged, notched P-wave duration indicative of BB delay, and RBBB, a dual-chamber conduction system pacemaker (Medtronic, Minneapolis, MN) was selected with a left bundle branch area pacing and BBAP strategy. Baseline conduction measurements were performed during sinus rhythm, which showed P-wave duration of 119 ms and PR interval of 135 ms (Figure 1A). Pace mapping of the BBA through the transvenous atrial lead (Medtronic 3830) indicated paced P-wave duration of 127 ms and paced PR interval of 159 ms when measuring from the onset of pacing stimulation (Figure 1B). When measuring from the onset of the paced P wave, paced P-wave duration of 101 ms and paced PR interval of 129 ms were observed (Figure 1C). Pacing from this location, correction of P-wave axis, reversal of notching, and decrease in P-wave duration when compared with baseline P wave measurements were consistent with BBAP. Given the evidence of BB capture, the transvenous atrial lead was implanted using standard implant techniques. The final sensing and threshold values at BBA implant site were 1.375mV and 1.5V at a 0.4-ms pulse width, respectively. Unfortunately, 2 weeks later, the patient exhibited evidence of a pacemaker pocket infection. Transvenous device removal and a leadless atrial pacemaker targeting BB were selected owing to SND, reduced risk for infection, decreased risk of AF, and the option for synchronous dual chamber pacing if needed in the future.Figure 1P wave and PR interval during sinus rhythm (A), transvenous atrial Bachmann’s bundle area pacing from onset of stim (B), and transvenous atrial Bachmann’s bundle area pacing from onset of paced P wave (C). BPM = beats per minute; Stim = distal electrode of right atrial lead. P wave and PR interval during sinus rhythm (A), transvenous atrial Bachmann’s bundle area pacing from onset of stim (B), and transvenous atrial Bachmann’s bundle area pacing from onset of paced P wave (C). BPM = beats per minute; Stim = distal electrode of right atrial lead. The transvenous dual chamber pacemaker was safely removed. The leadless atrial pacemaker implant portion of the procedure was performed under fluoroscopic and intracardiac echocardiographic (ICE) guidance. A decapolar catheter was advanced to the distal coronary sinus to the level of the left lateral atrium (LLA) near the left atrial appendage for electrogram recordings. A Nuvision 4-dimensional intracardiac echocardiogram catheter (Biosense Webster, Irvine, CA) was positioned in the right atrium (RA) for visualization of the RA, left atrium (LA), superior vena cava (SVC), right atrial appendage, aorta, and interatrial septum. A pigtail catheter was used to obtain contrast-enhanced fluoroscopy imaging of the SVC and superior RA, facilitating identification of the BB region in right anterior oblique 10° and left anterior oblique 10° (Supplemental Videos A and B in the Supplemental Data). Baseline conduction measurements were performed during sinus rhythm that showed P-wave duration 127 ms, PR interval of 151 ms, and P-wave onset to LLA conduction time of 106 ms (Figure 2A).Figure 2P wave, PR interval, and time to left lateral atrium during sinus rhythm (A), leadless atrial Bachmann bundle area pacing from onset of stimulation (B), and leadless atrial Bachmann bundle area pacing from onset of paced P wave (C). BPM = beats per minute; CS = coronary sinus. A. P wave, PR interval, and time to left lateral atrium during sinus rhythm (A), leadless atrial Bachmann bundle area pacing from onset of stimulation (B), and leadless atrial Bachmann bundle area pacing from onset of paced P wave (C). BPM = beats per minute; CS = coronary sinus. A. A leadless atrial pacemaker was advanced through the right femoral vein into the RA and positioned at the BBA identified through fluoroscopy and pace mapping. Sensing at this position was adequate. Pace mapping from the leadless atrial pacemaker indicated paced P-wave duration of 136 ms, paced PR interval of 166 ms, and leadless atrial pacemaker stimulation to LLA interval of 91 ms when measuring from the onset of pacing stimulation (Figure 2B). When measuring from the onset of the paced P wave, paced P-wave duration of 99 ms, paced PR interval of 129 ms, and leadless atrial pacemaker stimulation to LLA interval of 54 ms stimulation to LLA interval of 54 ms was observed (Figure 2C). The local electrogram at the BB site confirmed appropriate sensing and injury current. Pacing from this location also revealed earlier activation at the distal coronary sinus (CS) with a change in CS activation sequence, consistent with BBAP atrial resynchronization. Given the evidence of BB capture, the leadless atrial pacemaker was implanted using its active fixation helix delivery system, following standard implant techniques. ICE imaging and fluoroscopy were used to guide deployment. The final sensing and threshold values at BBA implant site were 1.3 mV and 1.75 V at a 0.4-ms pulse width, respectively. Figure 3A–3C illustrate the position of the BBA leadless device’s position in comparison with the previous transvenous BBA atrial lead’s position. 2-dimensional and 4-dimensional (4D) ICE imaging verified stable device fixation (Figure 4). Postimplantation pacing at the BBA confirmed the shortened P wave duration, preserved PR interval, and decreased stimulation to LA conduction time with change in left atrial activation compared with baseline. Post implant, 12-lead ECG showed improved P-wave duration, axis, and morphology compared with baseline, with very similar results to those in the prior transvenous paced P-wave morphology (Figure 5A–5C). The patient tolerated the procedure well without complications.Figure 3Comparison of fluoroscopic images of Bachmann bundle area pacing of transvenous atrial lead in left anterior oblique 10° (A), Bachmann bundle area pacing of atrial leadless pacemaker in left anterior oblique 10° (B), and right anterior oblique 10° (C).Figure 4Intracardiac echocardiographic guidance of leadless atrial pacemaker to Bachmann’s bundle target site. BBA = Bachmann bundle area.Figure 5A: Baseline electrocardiogram. B: Transvenous right atrial paced at Bachmann bundle area electrocardiogram. C: Leadless right atrial paced at Bachmann bundle area electrocardiogram. Comparison of fluoroscopic images of Bachmann bundle area pacing of transvenous atrial lead in left anterior oblique 10° (A), Bachmann bundle area pacing of atrial leadless pacemaker in left anterior oblique 10° (B), and right anterior oblique 10° (C). Intracardiac echocardiographic guidance of leadless atrial pacemaker to Bachmann’s bundle target site. BBA = Bachmann bundle area. A: Baseline electrocardiogram. B: Transvenous right atrial paced at Bachmann bundle area electrocardiogram. C: Leadless right atrial paced at Bachmann bundle area electrocardiogram. Discussion Traditional atrial pacing sites at RAA, transvenous or leadless, often worsen rather than alleviate atrial synchrony due to exacerbated IACD. IACD, defined as P-wave duration >120 ms, has been shown to be an independent predictor of AF. Moreover, pacing at the RAA may increase AF burden compared with pacing in the BBA.9 At baseline, the patient exhibited significant SND and IACD. Leadless pacing of BBA guided with ICE and fluoroscopy to confirm implant at the RA SVC junction and electrical guidance through documented advancement of the distal CS catheter bipole positioned at the LLA facilitated nearly identical outcomes for leadless and transvenous approaches. Compared with sinus rhythm in both transvenous and leadless BBA pacing, reduction in P-wave duration (when measuring from the onset of the paced P wave), P-wave axis correction, and elimination of P-wave notching were observed. Furthermore, reduced conduction time to the LLA was shown during leadless BBA pacing when measuring from both the onset of stimulation and onset of paced P wave when compared with sinus rhythm. The significance of latency observed on intracardiac tracings during transvenous and leadless pacing at BBA as observed in this case is unclear. This may be due to scar/fibrosis to this region or local tissue electrophysiologic properties unique to BBA.10 Latency due to poor tissue electrode interface in this case was unlikely given good sensing, threshold, and injury current were observed in both implant techniques. Lastly, both transvenous and leadless implant techniques relieved IACD without shortening the PR interval, an advantage that may prevent elevated LA pressure and reduce LA dilation by avoiding LA contraction against a closed mitral valve. This case provides the first direct comparison of permanent correction of underlying IACD using transvenous and leadless BBA implantation in the same patient. The results revealed the ability of leadless pacing at BBA to provide the same IACD alleviation as the transvenous pacemaker when comparing surface ECG P-wave axis, P-wave morphology, and P-wave duration. The procedure duration and fluoroscopy were comparable in both techniques. The transvenous implant was 72 minutes long, requiring 10.1 minutes of fluoroscopy compared with a procedure duration of 74 minutes requiring 15.5 minutes of fluoroscopy for the leadless implant. Although the implantation of permanent BBAP may be simpler and the probability of BB capture higher using transvenous leads, currently, leadless atrial pacemakers provide an alternative for patients with increased lead and pocket infection risk. In the first-in-human description of leadless pacemaker implant at BBA, the patient had several comorbidities and high infection risk, favoring a leadless device for the pacing strategy.8 In this patient, no comorbidities suggested she had an infection risk at the time of transvenous implant. Thus, stronger consideration for leadless BBAP may be considered for patients with atrial pacing needs only, such as SND, symptomatic bradycardia, and chronotropic incompetence, or in dual-chamber leadless implants to avoid adverse effects of RAA pacing. A shortcoming of the leadless approach with the Aveir AR (Abbott, Chicago, IL) device is the inability to pacemap from the device itself. Using a CS catheter to confirm advancement of the LLA and change in left atrial activation sequence can augment a strictly anatomical implantation at the RA/SVC border guided by ICE and fluoroscopy. The additional techniques, including 4D ICE and distal CS intracardiac measurements, were useful to enhance safety and confirm correction of IACD. As leadless BBAP techniques and tools improve, 4D ICE and intracardiac measurements may no longer enhance procedure safety and success. Because of anatomical variability and the limitations of current leadless atrial pacemaker delivery tools, leadless BBAP may not be possible in some patients. Future studies comparing outcomes of both transvenous and leadless at BBA and RAA pacing are needed. Conclusion This case indicates the ability of leadless BBAP to provide the same IACD correction and atrial resynchronization as standard transvenous BBAP. Intracardiac measurements confirmed LA activation over BB to the LLA with leadless pacing. By illustrating the ability for transvenous and leadless BBAP to achieve similar results, individualized atrial pacing strategies may be selected without sacrificing the benefits of BBAP. Funding Sources This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Disclosures Zachary T. Hollis is a consultant for Abbott, Medtronic, and Boston Scientific. Eunice Yang is a consultant for Medtronic and Eli Lilly. Brett D. Atwater is on a steering committee, receives research support, and is a consultant for Medtronic, Abbott, and Biosense Webster, and receives research support from Pfizer and BMS. Data availability The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available owing to privacy or ethical restrictions.